by San Rocco Therapeutics | May 19, 2023 | News
Patrick Girondi, Renowned Artist, Lends Support to Robert F. Kennedy Jr. in Goal of Accessible Healthcare for Americans Patrick Girondi, CEO of San Rocco Therapeutics (SRT) met Wednesday, May 17, 2023 with Robert F. Kennedy Jr. who is running for the Democratic Party...
by San Rocco Therapeutics | May 5, 2023 | News
RICO Lawsuit against pharma bosses San Rocco Therapeutics filed an action for violations of federal RICO (Federal Racketeering and Corrupt Organizations Act), fraudulent inducement and unfair business practices in the United States District court for the District of...
by San Rocco Therapeutics | Mar 15, 2023 | News
SRT Prevails Against Bluebird Bio: American Arbitration Association After San Rocco Therapeutics (SRT) founder Patrick Girondi’s son was diagnosed with Thalassemia in 1992, Girondi founded SRT. The mission of SRT is to develop an accessible cure for Thalassemia and...
by San Rocco Therapeutics | Jan 27, 2023 | News
Patrick Girondi Responds to New York Times on the Corrupt Expenses of Gene Therapy The high prices are caused by corruption and out of control executive compensations. Even small start-up research companies without products are compensating their executives and boards...
by San Rocco Therapeutics | Jan 16, 2023 | News
Gene Therapy For Thalassemia Needs To Be Safer Insertional oncogenesis is an inherent risk of lentiviral vectors because they are able to integrate into thousands of loci within the genome. Bluebird’s Lenti-D integrated into 1 or more oncogenes in nearly all 67 trial...
by San Rocco Therapeutics | Sep 11, 2022 | News
LA Times Piece Glosses Over Gritty Realities Beta Thalassemia Gene Therapy: Bluebird Bio vs. San Rocco Therapeutics SRT gene therapy vector, since 2012, two out of three patients treated with myelosuppression and the SRT investigational product produced in 2009-2019...
